Neurosense Therapeutics is trading at $4.40, down 13.56%, with no clear company-specific catalyst identified for the September 29 decline. - The latest announcement was the CFO’s participation in a healthcare investor conference, not a newly announced financial or clinical milestone. - The September 29 Nasdaq compliance deadline is relevant background, but available evidence does not establish it as the direct cause. - Broader indices were modestly lower in the supplied context, so market sentiment cannot be confidently identified as the cause.